AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clonal Architecture of ASXL1-mutated Myelofibrosis

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Angers
💬

In plain words

What the trial is, and whether it could suit you

Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adults (age ≥18 years), * Affiliated to the national social security system, * ASXL1 mutated primary or secondary myelofibrosis, * Signed the consent to participate in the study, * Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM). Exclusion Criteria: * Patient with another active hematological disease or cancer at the time of diagnosis, * Person subject to legal protection scheme or incapable of giving consent.
💊

What it tests

  • Clonal architecture determination
📍

Where

13 sites
CHU Angers
Angers, France
CHRU Brest
Brest, France
CH Cholet
Cholet, France
CHU Henri MONDOR
Créteil, France
Institut Paoli Calmettes
Marseille, France
CHU Nantes
Nantes, France
AP-HP Hôpital Saint Louis
Paris, France
Hôpital Bicêtre
Paris, France

…and 5 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy